Skip to content

Determining When Patients Hospitalized With Acute Heart Failure Can Be Safely Sent Home (The DECIDE Study)

Treatment Endpoints in Acute Decompensated Heart Failure

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00911703
Acronym
DECIDE
Enrollment
835
Registered
2009-06-02
Start date
2008-08-31
Completion date
2015-10-31
Last updated
2016-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Heart Failure

Brief summary

The purpose of this study is to determine if certain findings (blood tests, symptom improvement, etc.) after acute heart failure treatment can identify a group of patients who are safe for early hospital discharge.

Detailed description

A fundamental question faced by physicians treating acute decompensated heart failure (ADHF) is When has treatment worked sufficiently for safe discharge, and who requires further treatment? Patients with ADHF have a high incidence of morbidity and mortality. Current guidelines for emergency department (ED) and hospital disposition of patients with ADHF are based on limited empirical evidence. This creates clinical uncertainty regarding disposition leads to prolonged hospitalizations, higher costs and increased resource consumption. The specific aim of the study is to develop a prediction rule from readily available clinical data to help physicians identify ADHF patients eligible for safe and early discharge from the ED and hospital after treatment is initiated.

Interventions

None listed

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
Abbott Point of Care
CollaboratorINDUSTRY
Inovise Medical
CollaboratorINDUSTRY
Vanderbilt University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Fulfill the modified Framingham criteria * Have baseline data available within 1 hour of initial ED therapy * Have previously documented systolic dysfunction (ejection fraction less than 50%) by echocardiogram * Willing and able to give informed consent The

Exclusion criteria

are: * Patients less than 18 years of age.

Design outcomes

Primary

MeasureTime frame
Heart-failure related adverse eventsMeasured 5 days and 30 days after ED presentation

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026